Financial information

Financial guidance 2018*

MorphoSys expects Group revenues for the 2018 financial year in the range of EUR 67 to 72 million. R&D expenses for proprietary drug development are expected to rise to EUR 87 to 97 million. The Company expects earnings before interest and taxes (EBIT) in a range of between EUR -55 to -65 million. This guidance does not include any potential in-licensing or co-development of further development candidates.

in € million

Guidance 2018*
(updated July 19, 2018)

Guidance 2018
(issued March 13, 2018)

Results 2017

Group Revenues 67 to 72 20 to 25 66.8
R&D expenses Proprietary Development 87 to 97 95 to 105 99.1
Group EBIT -55 to -65 -110 to -120 - 67.6

*The guidance update follows the signature of a deal with Novartis on MOR106 and is still subject to U.S. antitrust clearance.

Fundamentals of
MorphoSys Group

Business Segments

MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of therapeutic antibodies. MorphoSys is committed to create significant value for its employees, shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potentials. 

PARTNERED DISCOVERY

MorphoSys's Partnered Discovery segment business applies the Company's proprietary technologies to the research, development and optimization of therapeutic antibody drug candidates in partnerschips with pharmaceutical and biotechnology companies. While the development costs are borne by the respective partner, MorphoSys profits further from successful programs via milestone payments and potential royalties on product sales.

PROPRIETARY DEVELOPMENT

In the second segment, Proprietary Development, MorphoSys develops innovative proprietary antibody products to generate added value for the Company. MorphoSys's scientists concentrate on indications such as inflammatory and autoimmune diseases, as well as cancer and infectious diseases. In this segment, the compounds are developed independently (or in a co-development setting) to proof clinical efficacy before being out-licensed to pharmaceutical or biotechnology companies for late-stage development and marketing.

More information about our proprietary product portfolio can be found here.

Related Links

Financial Reports

 
PDF-Download
Online Version
Order Printed Version

2018

  1. Half-Year Report 2018

    Download
    Online
    Order
     
  2. 1st Quarter Interim Statement 2018

    Download
    Online
    Order
     

2017

  1. Financial Statements 2017 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. 3rd Quarter Interim Statement 2017

    Download
    Online
    Order
     
  3. Half-Year Report 2017

    Download
    Online
    Order
     
  4. 1st Quarter Interim Statement 2017

    Download
    Online
    Order
     

2016

  1. Annual Report 2016

    Download
    Online
    Order
  2. Financial Statements 2016 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. 3rd Quarter Interim Statement 2016

    Download
    Online
    Order
     
  4. Half-Year Report 2016

    Download
    Online
    Order
     
  1. 1st Quarter Interim Statement 2016

    Download
    Online
    Order
     

2015

  1. Financial Statements 2015 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2015

    Download
    Online
    Order
     
  3. Nine Months' Report 2015

    Download
    Online
    Order
     
  4. Six Months' Report 2015

    Download
    Online
    Order
     
  5. Three Months’ Report 2015

    Download
    Online
    Order
     

2014

  1. Financial Statements 2014 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2014

    Download
    Online
    Order
     
  3. Nine Months' Report 2014

    Download
    Online
    Order
     
  4. Six Months' Report 2014

    Download
    Online
    Order
     
  5. Three Months' Report 2014

    Download
    Online
    Order
     

2013

  1. Financial Statements 2013 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  2. Consolidated Financial Statements (IFRS) 2013

    Download
    Online
    Order
     
  3. Nine Months' Report 2013

    Download
    Online
    Order
     
  4. Six Months' Report 2013

    Download
    Online
    Order
     
  5. Three Months' Report 2013

    Download
    Online
    Order
     

2012

  1. Consolidated Financial Statements (IFRS) 2012

    Download
    Online
    Order
     
  2. Financial Statements 2012 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2012

    Download
    Online
    Order
     
  4. Six Months' Report 2012

    Download
    Online
    Order
     
  5. Three Months' Report 2012

    Download
    Online
    Order
     

2011

  1. Consolidated Financial Statements (IFRS) 2011

    Download
    Online
    Order
     
  2. Financial Statements 2011 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2011

    Download
    Online
    Order
     
  4. Six Months' Report 2011

    Download
    Online
    Order
     
  5. Three Months' Report 2011

    Download
    Online
    Order
     

2010

  1. Consolidated Financial Statements (IFRS) 2010

    Download
    Online
    Order
     
  2. Financial Statements 2010 of MorphoSys AG (German GAAP - HGB)

    Download
    Online
    Order
     
  3. Nine Months' Report 2010

    Download
    Online
    Order
     
  4. Six Months' Report 2010

    Download
    Online
    Order
     
  5. Three Months’ Report 2010

    Download
    Online
    Order
     

In-house produced with firesys